CLINICAL_TRIALS
trial_result
· 2022-02-09
Clinical Trial Update: A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy [Phase 2]
Summary
This clinical trial update reports results from a Phase 2 study of acalabrutinib (ACP-196) in subjects with relapsed/refractory chronic lymphocytic leukemia who…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-02-09